New hope for rare kidney disease: iptacopan shows promise in early access study
NCT ID NCT07598448
First seen May 22, 2026 · Last updated May 22, 2026
Summary
This study reviews the experience of 35 adults with complement 3 glomerulopathy (C3G), a rare kidney disease, who received the drug iptacopan through an early access program in Spain. Researchers will look at patient characteristics, lab results, and how the disease responds to treatment. The goal is to better understand who benefits from iptacopan and how it works in real-world settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEMENT 3 GLOMERULOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.